Published in Proc Natl Acad Sci U S A on July 22, 1997
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 2.78
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell (2014) 1.91
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res (2009) 1.77
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 1.71
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther (2010) 1.33
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A (2000) 1.31
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol (2012) 1.30
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A (2008) 1.22
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood (2006) 1.14
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol (2014) 1.11
Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res (2010) 1.06
Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection. Clin Exp Immunol (1999) 1.04
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood (2005) 1.04
Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 1.04
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med (2011) 1.01
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol (2001) 1.00
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98
Immune regulatory antibodies: are they the next advance? Cancer J (2010) 0.97
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol (2006) 0.97
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res (2015) 0.97
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw (2014) 0.96
Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer (2013) 0.95
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother (2011) 0.93
Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate (2010) 0.91
The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol (2010) 0.90
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer (2012) 0.89
Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J Biol Med (2011) 0.88
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer (2015) 0.87
Use of ipilimumab in the treatment of melanoma. Clin Pharmacol (2013) 0.86
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol (2016) 0.86
Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy. Int J Mol Sci (2014) 0.84
Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model. Cancer Immunol Immunother (2011) 0.83
Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther (2014) 0.83
Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells. Cancer Gene Ther (2010) 0.82
Combining Vaccines with Conventional Therapies for Cancer. Update Cancer Ther (2007) 0.82
Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol (2012) 0.82
From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int (2014) 0.81
Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7. Stem Cells Dev (2016) 0.80
Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol (2011) 0.80
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol (2015) 0.79
The wonderous chaperones: A highlight on therapeutics of cancer and potentially malignant disorders. J Oral Maxillofac Pathol (2015) 0.78
Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol (2012) 0.78
Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clin Cancer Res (2016) 0.77
Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy (2009) 0.77
Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother (2016) 0.76
Immune Therapy for Prostate Cancer. Cancer J (2016) 0.76
Immunotherapy in genitourinary malignancies. Curr Opin Urol (2016) 0.75
Elimination of T cell reactivity to pancreatic β cells and partial preservation of β cell activity by peptide blockade of LFA-1:ICAM-1 interaction in the NOD mouse model. Clin Immunol (2013) 0.75
Predicting analysis times in randomized clinical trials with cancer immunotherapy. BMC Med Res Methodol (2016) 0.75
Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer. Oncol Lett (2017) 0.75
Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. J Clin Invest (2015) 0.75
Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. World J Urol (2000) 0.75
Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by SIVΔnef live attenuated vaccine. PLoS One (2017) 0.75
CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation. Cell Death Differ (2017) 0.75
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 8.16
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
Cancer statistics, 1997. CA Cancer J Clin (1997) 5.22
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 3.73
Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol (1991) 2.36
The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev (1996) 2.18
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01
Natural killer cells: from no receptors to too many. Immunity (1997) 1.96
A transgenic mouse prostate cancer model. Toxicol Pathol (1997) 1.91
Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1) Immunity (1996) 1.69
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol (1996) 1.69
Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res (1994) 1.33
CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol (1994) 1.18
Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol (1994) 1.17
Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res (1994) 1.08
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol (1982) 5.92
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 5.32
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
Effect of vasopressin and cyclic AMP on permeability of isolated collecting tubules. Am J Physiol (1966) 4.19
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell (1988) 3.88
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res (1997) 3.67
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Function of the thick ascending limb of Henle's loop. Am J Physiol (1973) 3.48
Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature (1988) 3.48
Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37
Control of fluid absorption in the renal proximal tubule. J Clin Invest (1968) 3.10
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 2.78
Renal medullary organic osmolytes. Physiol Rev (1991) 2.74
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 2.72
Costimulatory regulation of T cell function. Curr Opin Cell Biol (1999) 2.69
The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med (1987) 2.52
Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science (1991) 2.49
Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature (1987) 2.38
Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis (1999) 2.37
Co-stimulation in T cell responses. Curr Opin Immunol (1997) 2.35
Refined structure of alkaline phosphatase from Escherichia coli at 2.8 A resolution. J Mol Biol (1985) 2.31
Cloning of the cDNa for a Na+/myo-inositol cotransporter, a hypertonicity stress protein. J Biol Chem (1992) 2.28
Ion transport in cortical collecting tubule; effect of amiloride. Am J Physiol (1974) 2.18
The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev (1996) 2.18
Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol (1987) 2.17
Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res (1997) 2.16
Perfusion of isolated renal tubules. Yale J Biol Med (1973) 2.12
Ultrastructural studies of vasopressin effect on isolated perfused renal collecting tubules of the rabbit. J Cell Biol (1968) 2.06
The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell (1983) 2.04
Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature (1987) 2.00
Electrical properties of isolated perfused rabbit renal tubules. Am J Physiol (1968) 1.98
CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med (1993) 1.93
Cloning of a Na(+)- and Cl(-)-dependent betaine transporter that is regulated by hypertonicity. J Biol Chem (1992) 1.93
A transgenic mouse prostate cancer model. Toxicol Pathol (1997) 1.91
Electrical potential difference across proximal convoluted tubules. Am J Physiol (1970) 1.86
Identification of antigen receptor-associated structures on murine T cells. Nature (1985) 1.79
Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology (1996) 1.74
The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol (1990) 1.74
Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature (1990) 1.73
Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature (1989) 1.73
Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem (2001) 1.73
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A (1999) 1.70
Glucose transport by proximal renal tubules. Am J Physiol (1971) 1.69
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol (1996) 1.69
Effect of vasopressin on sodium transport in renal cortical collecting tubules. Kidney Int (1972) 1.68
Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A (1997) 1.67
Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res (2001) 1.66
Effect of vasopressin on electrical resistance of renal cortical collecting tubules. Am J Physiol (1971) 1.65
Cell cycle delay and apoptosis are induced by high salt and urea in renal medullary cells. Am J Physiol Renal Physiol (2000) 1.64
Bicarbonate transport by rabbit cortical collecting tubules. Effect of acid and alkali loads in vivo on transport in vitro. J Clin Invest (1977) 1.61
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res (2001) 1.59
Mineralocorticoid effects on cation transport by cortical collecting tubules in vitro. Am J Physiol (1978) 1.58
Ammonia and bicarbonate transport by thick ascending limb of rat kidney. Am J Physiol (1984) 1.58
The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol (2001) 1.57
Paths of transtubular water flow in isolated renal collecting tubules. J Cell Biol (1969) 1.57
Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene (2000) 1.57
Molecular cloning of cDNA coding for kidney aldose reductase. Regulation of specific mRNA accumulation by NaCl-mediated osmotic stress. J Biol Chem (1989) 1.56
Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. Proc Natl Acad Sci U S A (1989) 1.49
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
Macromolecular crowding and confinement in cells exposed to hypertonicity. Am J Physiol (1994) 1.46
Mineralocorticoid effects on Na-K-ATPase in individual nephron segments. Am J Physiol (1981) 1.45
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol (1998) 1.45
Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl (1993) 1.44
HTF4: a new human helix-loop-helix protein. Nucleic Acids Res (1991) 1.43
Characteristics of p-aminohippurate transport in proximal renal tubules. Am J Physiol (1969) 1.43
The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res (1999) 1.42
Bicarbonate secretion and chloride absorption by rabbit cortical collecting ducts. Role of chloride/bicarbonate exchange. J Clin Invest (1985) 1.41
Role of organic osmolytes in adaptation of renal cells to high osmolality. J Membr Biol (1991) 1.41
Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. Nature (1988) 1.41
Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol (1993) 1.39
Characteristics of NaCl and water transport in the renal proximal tubule. J Clin Invest (1971) 1.37